LinkedInXFacebook
Subscribe
Orthopedics This Week
  • My Feed
  • |Posts
  • |Events
  • |MSK Innovations
  • |Power Rankings
  • |Masterclasses
  • |Technology Awards
  • Press Releases
  • |Advertising
  • |Job Board
  • Spine
  • ◆Joints
  • ◆Upper Extremities
  • ◆Foot & Ankle
  • ◆Sports Medicine
  • ◆Pain Mgmt
  • ◆Trauma
  • ◆Biologics
  • ◆Technology
  • ◆People
  • ◆Company News
  • ◆Legal & Regulatory
Home/People In The News/Constance Chu, M.D. Receives Kappa Delta AND $10 Million
People In The News

Constance Chu, M.D. Receives Kappa Delta AND $10 Million

March 8, 2019 2 min read Premium comments

Advertisement

Constance Chu, M.D. Receives Kappa Delta AND $10 Million
Constance Chu, M.D.
#osteoarthritis#kappadeltaaward#constancechu

Constance Chu, M.D., professor and vice chair of Research in the Department of Orthopedic Surgery at Stanford University, is set to receive not only an award for her research, but the most substantial research grant in the history of the department—all in recognition of her efforts to prevent osteoarthritis (OA).

Dr. Chu will receive the Kappa Delta Award at the meeting of The American Academy of Orthopaedic Surgeons on March 14 in Las Vegas. The award includes $20,000, part of which she will invest in future research and a portion of which will be shared with her team.

“It is really a huge honor,” Chu said, adding that the award is sometimes referred to as the Nobel Prize in orthopedic surgery. “Our work early on was viewed with some skepticism, but our persistence and teamwork have paid off.”

Also notable is the $10 million grant awarded last fall to Dr. Chu and her team from the U.S. Department of Defense. She is set to undertake clinical trials to study ways to prevent osteoarthritis from occurring after an injury.

Dr. Chu is conducting five studies using this grant, including two clinical trials that will test new strategies to prevent osteoarthritis. One trial will focus on how patients walk after injury and whether improving their gait can prevent the condition from developing. Another will involve testing gene therapy in horses, which develop osteoarthritis similar to the way humans do. The team will also examine preventive medications, stem cell therapies and the molecular changes that lead to the deterioration of cartilage.

Asked why she decided to focus on OA prevention, Dr. Chu told OTW, “I love a good challenge, so I started trying to regenerate articular cartilage because Henry Mankin said no one had been able to figure out the cartilage problem and tossed me the gauntlet during medical school. After being introduced to osteochondral allografts by Wayne Akeson and trying to create tissue engineered osteochondral grafts in David Amiel’s lab as a resident, I gained a better appreciation for the enormity of Mankin’s challenge and started thinking about how to maintain that pristine articular surface. Thus, my focus was always on prevention.”

“While mechanical loading is critical to joint health and development, cumulative mechanical overload destroys joints. Walking is a basic activity and we all should take at least 10,000 steps a day. Thus, optimizing gait mechanics can have a large effect on modulating a decades long process with a strong mechanical component such as OA development.”

“We all treat joint injuries which fast track many joints toward OA development. Our research shows about half of patients have signs of what we call ‘’pre-osteoarthritis,’ as early as 1 to 2 years after anterior cruciate ligament injury and reconstruction. The newly funded clinical trials will evaluate a number of early treatment strategies for patients at or near the time of joint injury to reduce OA risk. These developments are important to anyone treating joints—whether large or small.”

React:

Discussion

14
DS
Dr. Sarah MitchellOrthopedic Surgeon · Mayo Clinic

This is a fascinating development. In my practice we've seen similar outcomes with the revised protocol. The key differentiator seems to be patient selection criteria. Has anyone else noticed the correlation with BMI thresholds?

8
JT
James Thornton, MDSpine Fellow · HSS

Great point. I'd push back slightly on the conclusion, the sample size in the cited study is too small to draw population-level inferences. That said, the directional signal is compelling and worth a larger RCT.

5
RP
R. PatelSports Medicine · Stanford

We implemented a similar approach last year. Early results are promising but we're still gathering 12-month follow-up data. Happy to share our protocol if anyone is interested.

Join the conversation

Orthopedic professionals are discussing this. Sign in and upgrade to read every comment and add your voice.

Subscribe

Get Full Access

Read every OTW article and join member discussions for $24.99/month.

Get Full Access

Advertisement

Advertisement

Advertisement

Orthopedics This Week

The most trusted source in orthopedic industry news since 2005. Covering spine, joints, trauma, biologics, and the business of orthopedics.

A publication of RRY Publications, LLC

LinkedInXFacebook

Categories

  • Spine
  • Joints
  • Upper Extremities
  • Foot & Ankle
  • Sports Medicine
  • Pain Mgmt
  • Trauma
  • Biologics
  • Technology
  • People
  • Company News
  • Legal & Regulatory

Resources

  • Subscribe
  • Community Posts
  • Job Board
  • Press Release Opportunities
  • Power Rankings
  • About OTW
  • Advertise
  • Contact Us

Get Full Access

Unlimited articles, community posts, and Power Rankings.

Get Full Access

Plans start at $24.99/mo · Annual saves 20%

© 2026 Orthopedics This Week · RRY Publications, LLC

Privacy PolicyTerms of ServiceCookie Policy